Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Financing Activities (2023 - 2025)

Compass Therapeutics' Cash from Financing Activities history spans 3 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 1230.85% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $129.6 million, up 647.54%, while the annual FY2025 figure was $129.6 million, 647.54% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $1.1 million at Compass Therapeutics, down from $129.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $129.4 million in Q3 2025 and bottomed at -$815000.0 in Q1 2025.
  • The 3-year median for Cash from Financing Activities is $21000.0 (2023), against an average of $13.6 million.
  • The largest annual shift saw Cash from Financing Activities crashed 109.52% in 2024 before it surged 6468150.0% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at -$158000.0 in 2023, then soared by 40.51% to -$94000.0 in 2024, then skyrocketed by 1230.85% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Cash from Financing Activities are $1.1 million (Q4 2025), $129.4 million (Q3 2025), and -$815000.0 (Q1 2025).